Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B (ELIMINATE-B)
A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Precision Trial Manager
- Phone Number: 800-371-8953
- Email: ELIMINATE-B@precisionbiosciences.com
Study Locations
-
-
France
-
Clichy, France, France, 92110
- Recruiting
- Hospital Beaujon
-
Contact:
- Tarik Asselah, MD
- Phone Number: 33140875514
- Email: tarik.asselah@aphp.fr
-
Contact:
- Stephanie Narguet
- Phone Number: 33140875514
- Email: stephanie.narguet@aphp.fr
-
Principal Investigator:
- Tarik Asselah, MD
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong
- Recruiting
- Queen Mary Hospital, The University of Hong Kong
-
Contact:
- Man-Fung Yuen, MBBS, MD, PhD, DSc
- Phone Number: 852-2255 3579
- Email: mfyuen@hku.hk
-
Principal Investigator:
- Man-Fung Yuen, MBBS, MD, PhD, DSc
-
-
-
-
-
Chisinau, Moldova, 2025
- Recruiting
- ICS ARENSIA Exploratory Medicine SRL
-
Contact:
- Manager, Projects & Research Logistics
- Phone Number: 373-78883368
- Email: alexei.haceatrean@arensia-em.com
-
-
-
-
-
Auckland, New Zealand, 1010
- Recruiting
- New Zealand Clinical Research
-
Contact:
- Edward Gane, MD
- Phone Number: 64-2-154-8371
- Email: EdGane@adhb.govt.nz
-
Contact:
- Sophie Townshend, Study Coordinator
- Phone Number: 64-9-373-3474
- Email: sophie.townshend@nzcr.co.nz
-
Principal Investigator:
- Edward Gane, MD
-
-
-
-
Romania
-
Bucharest, Romania, Romania, 021105
- Recruiting
- ARENSIA Exploratory Medicine
-
Contact:
- Anca Streinu Cercel, MD
- Phone Number: 40722998425
- Email: anca.streinucercel@gmail.com
-
Contact:
- Coralia-Alexandra Caluian
- Phone Number: 40727193218
- Email: coralia.caluian@arensia-em.com
-
Principal Investigator:
- Anca Streinu Cercel, MD
-
Cluj-Napoca, Romania, Romania, 400006
- Recruiting
- Arensia Exploratory Medicine in collaboration with County Clinical Emergency Hospital
-
Contact:
- Vlad-Andrei Ichim, MD
- Phone Number: 40751130280
- Email: vlad.ichim.ext@arensia-em.com
-
Contact:
- Emanuela Beni
- Phone Number: 40711912839
- Email: emanuela.beni@arensia-em.com
-
Principal Investigator:
- Vlad-Andrei Ichim, MD
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital/Harvard University
-
Contact:
- Raymond T Chung, MD
- Phone Number: 617-724-75
- Email: Chung.Raymond@mgh.harvard.edu
-
Principal Investigator:
- Raymond T Chung, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Male or women of non-child bearing potential
- BMI 18.0 to 35.0
- Good overall health deemed by the study Investigator
- CHB infection documented at least 12 months prior to screening
- HBeAg-negative CHB
- Must be virologically suppressed on current NA treatment
Key Exclusion Criteria:
- No history of cirrhosis of the liver
- No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant.
- No signs of hepatocellular carcinoma
- Not received an organ transplant
- No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer)
- No investigational agent received within 6 months of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants in both Part 1 and 2 will receive a finite course of PBGENE-HBV.
All participants will receive a finite course of multiple IV dose administrations of PBGENE-HBV.
In Part 1, this will be done in a dose escalation manner which may be evaluated further in a Part 2 expansion cohort.
|
PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety to Assess Treatment-emergent Adverse Events (TEAEs)
Time Frame: 4 weeks after final dose
|
Frequency of TEAEs
|
4 weeks after final dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Additional Safety
Time Frame: 48 weeks
|
Frequency and severity of adverse events and changes in physical examinations, vital signs, and safety labs (hematology, chemistry, and urinalysis)
|
48 weeks
|
|
Pharmacokinetics of AUC
Time Frame: 4 weeks
|
Total PBGENE-HBV exposure over time
|
4 weeks
|
|
Pharmacokinetics of Cmax
Time Frame: 4 weeks
|
Time at which Cmax (maximum peak concentration of PBGENE-HBV) is observed
|
4 weeks
|
|
Pharmacokinetics of Cmin
Time Frame: 4 weeks
|
Minimum (or trough) concentration of PBGENE-HBV
|
4 weeks
|
|
Pharmacokinetics of half life (t1/2)
Time Frame: 4 weeks
|
Terminal half life
|
4 weeks
|
|
Antiviral Activity of HBsAg and Anti-HBs
Time Frame: 48 weeks
|
Changes from baseline in hepatitis B surface antigen (HBsAg) and anti-HBs levels
|
48 weeks
|
|
Antiviral Activity of HBV DNA
Time Frame: 48 weeks
|
Changes from baseline of HBV DNA
|
48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Oby Sogbetun Medical Monitor, MD, Precision BioSciences, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Infections
- Virus Diseases
- Digestive System Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Pathological Conditions, Signs and Symptoms
- Hepatitis B
- Hepatitis B, Chronic
Other Study ID Numbers
Other Study ID Numbers
- PBGENE-HBV-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.